polatuzumab vedotin
roche
['polatuzumab', 'dlbcl']
#ash22 adding the antibody drug-conjugate #polatuzumab #vedotin to a standard chemotherapy-based second-line regimen resulted in a high complete response rate among patients with relapsed/refractory #dlbcl 
A magazine from @ASH_Hematology offering news and views for the broader hematology/oncology community.